疏肝健脾法对肝癌肝动脉化疗栓塞后免疫功能的影响

Effect of Shuganjianpi Therapy on Immunologic Function after Transcatheter Arterial Chemoembolization in Liver Cancer Patients

目的探讨疏肝健脾法对肝癌患者肝动脉化疗栓塞后免疫功能的影响。方法103例中晚期原发性肝癌患者随机分为治疗组(n=52)及对照组(n=51)。两组患者介入治疗后均予西药常规护肝治疗及对症处理,治疗组在介入治疗前7 d开始服用疏肝健脾中药,介入治疗后随症加减,对照组单纯行肝动脉化疗栓塞。两组患者分别在第1次介入前、第2次介入后4周检查T淋巴细胞亚群。结果第1次介入前治疗组和对照组的NK细胞、CD3、CD4、CD4/CD8比值差异无显著性,P均>0.05。第2次介入后4周对照组的NK细胞、CD3、CD4、CD4/CD8比值均下降;而治疗组的NK细胞、CD3、CD4、CD4/CD8比值均升高,与治疗前比较有统计学意义,P均<0.05。结论疏肝健脾法可提高肝癌患者TACE后的免疫功能。

Objective To study the effect of Shuganjianpi therapy（SGJPT） on the immunologic function after transcatheter arterial chemoembolization（TACE） in liver cancer patients.Methods A total of 103 patients with mid-advanced primary hepatic carcinoma were randomly divided into two groups,i.e.trial group and control group.Western medicines were used to protect hepatic function and alleviate symptoms after TACE in all the 103 patients.Since seven days before TACE,the patients in the trial group had been taking SGJP herbal medicine,which was ＂plus＂ or ＂minus＂with the symptoms after TACE.TACE was used in the control group alone.T lymphocyte subgroup was measured in both the two groups before the first TACE and four weeks after the second TACE,respectively.Results Although there were no significant differences in nature killer cell,CD3,CD4 and CD4/CD8 ratio between the two groups before the first TACE,the above parameters all decreased in the control group and increased in the trial group four weeks after the second TACE,which indicated significant differences between the two groups（P〈0.05）.Conclusion Shuganjianpi therapy can advance immunologic function of liver cancer patients after transcatheter arterial chemoembolization.